Several α7 nAChR partial agonists have shown potential in the treatment of AD [6, 7] but either the procognitive effects were not reproducible [8] or the trials are currently on clinical hold, apparently due to safety concerns related to gastrointestinal side effects [9]. Here, CHRNA7 is linked to Alzheimer disease.